Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9% [Yahoo! Finance]
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
Tempus AI (TEM) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.
Tempus AI (TEM) is now covered by Jefferies Financial Group Inc.. They set an "underperform" rating and a $35.00 price target on the stock.